title: Poor antibody validation is a challenge in biomedical research: a case study for detection of c-FLIP.
abstract: Successful translation of findings derived from preclinical studies into effective therapies is critical in biomedical research. Lack of robustness and reproducibility of the preclinical data, due to insufficient number of repeats, inadequate cell-based and mouse models contribute to the poor success rate. Antibodies are widely used in preclinical research, notably to determine the expression of potential therapeutic targets in tissues of interest, including tumors, but also to identify disease and/or treatment response biomarkers. We sought to determine whether the current antibody characterization standards in preclinical research are sufficient to ensure reliability of the data found in peer-reviewed publications. To address this issue, we used detection of the protein c-FLIP, a major factor of resistance to apoptosis, as a proof of concept. Accurate detection of endogenous c-FLIP levels in the preclinical settings is imperative since it is considered as a potential theranostic biomarker. Several sources of c-FLIP antibodies validated by their manufacturer and recommended for western blotting were therefore rigorously tested. We found a wide divergence in immune recognition properties. While these antibodies have been used in many publications, our results show that several of them failed to detect endogenous c-FLIP protein by Western blotting. Our results suggest that antibody validation standards are inadequate, and that systematic use of genetic knockdowns and/or knockouts to establish proof of specificity is critical, even for antibodies previously used in the scientific literature. Because antibodies are fundamental tools in both preclinical and clinical research, ensuring their specificity is crucial.
authors.affiliation: Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA, 02215, USA.
authors.forename: Octavian
authors.initials: O
authors.lastname: Bucur
authors.forename: Bodvael
authors.initials: B
authors.lastname: Pennarun
authors.forename: Andreea Lucia
authors.initials: AL
authors.lastname: Stancu
authors.forename: Monica
authors.initials: M
authors.lastname: Nadler
authors.forename: Maria Sinziana
authors.initials: MS
authors.lastname: Muraru
authors.forename: Thierry
authors.initials: T
authors.lastname: Bertomeu
authors.forename: Roya
authors.initials: R
authors.lastname: Khosravi-Far
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology*; D000918:Antibody Specificity; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein / Q000276:immunology* / Q000378:metabolism; D045744:Cell Line, Tumor; D006801:Humans; D051379:Mice; D011817:Rabbits
chemical_list: D000906:Antibodies; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein; C506386:CFLAR protein, human